使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good morning, ladies and gentlemen and welcome to Baxter International's first quarter earnings conference call. Your lines will remain in a listen-only mode until the question-and-answer segment of today's call.
各位女士、先生,早安,歡迎參加百特國際第一季財報電話會議。在今天電話會議的問答環節開始前,您的線路將維持僅收聽模式。
(Operator Instructions)
(接線員指示)
As a reminder, this call is being recorded by Baxter and is copyrighted material and cannot be recorded or rebroadcast without Baxter's permission. If you have any objections, please disconnect at this time. I would now like turn the call over to Ms. Mary Kay Ladone, Corporate Vice President Investor Relations at Baxter International. Ms. Ladone, you may begin.
提醒各位,本通話由百特錄音,並屬受版權保護之資料,未經百特許可不得錄音或轉播。如您有任何異議,請此刻中斷連線。現在我想將電話會議交給百特國際企業副總裁暨投資人關係負責人 Mary Kay Ladone 女士。Ladone 女士,請開始。
- Corporate VP, IR
- Corporate VP, IR
Thanks, Sean, good morning and welcome to our first-quarter 2012 earnings conference call. Are joining me today are Bob Parkinson, CEO and Chairman of Baxter International, Bob Hombach, Chief Financial Officer, and Dr. Norbert Riedel, Chief Science and Innovation Officer. Before we get started, let me remind you that this presentation including comments regarding our financial outlook, new product developments and regulatory matters contain forward-looking statements that involve risks and uncertainties and of course our actual results could differ materially from our current expectations.
謝謝你,Sean,早安,歡迎參加我們 2012 年第一季財報電話會議。今天與我一同出席的有百特國際執行長暨董事長 Bob Parkinson、財務長 Bob Hombach,以及首席科學與創新長 Norbert Riedel 博士。在開始之前,提醒各位,本簡報包含對我們財務展望、新產品開發及法規事項的評論,屬前瞻性陳述,涉及風險與不確定性,當然實際結果可能與我們目前的預期有重大差異。
Please refer to today's press release and our SEC filings for more detail concerning factors that could cause actual results to differ materially. In addition, in today's call, non-GAAP financial measures will be used to investors understand Baxter's ongoing business performance. A reconciliation of the non-GAAP financial measures being discussed today to the comparable GAAP financial measures is included in our earnings release issued this morning and available on our website. Now I'd like to turn the call over to Bob Parkinson.
請參閱今日新聞稿及我們向美國證券交易委員會(SEC)提交的文件,以取得可能導致實際結果與預期有重大差異之因素的更多細節。此外,在今天的電話會議中,我們將使用非 GAAP 財務衡量指標,以協助投資人了解百特持續性業務表現。今日所討論之非 GAAP 財務衡量指標與可比較之 GAAP 財務衡量指標的調節表,已包含於我們今早發布並可於網站取得的財報新聞稿中。現在我想把電話交給 Bob Parkinson。
- Chairman, CEO
- Chairman, CEO
Thanks, Mary Kay, good morning; thanks for calling in. We're pleased today to announce our financial results for the first quarter and also provide you with an update on our full-year 2012 outlook. As you all saw in our press release that was issued earlier this morning, EPS of $1.01 per diluted share exceeded our guidance, and increased 3% versus the prior-year on an adjusted basis. First quarter sales, after adjusting for FX, increased 4% and exceeded our sales growth guidance of approximately 2%. Our strong financial position continues to provide us the flexibility to make investments to grow our core product portfolio, expand further in developing in emerging markets, advance our pipeline, and pursue opportunities that will position us for the future all with an eye toward delivering enhanced value to our shareholders.
謝謝你,Mary Kay,早安;感謝各位來電參與。我們很高興今天公布第一季財務結果,並向各位更新我們 2012 全年展望。如各位今早稍早發布的新聞稿所見,稀釋後每股盈餘(EPS)為 1.01 美元,優於我們的指引,並在調整後基礎上較去年同期成長 3%。第一季銷售額在剔除匯率(FX)影響後成長 4%,並高於我們約 2% 的銷售成長指引。我們強健的財務狀況持續提供彈性,使我們得以投資以成長核心產品組合、在新興市場進一步擴張、推進研發管線,並把握能讓我們為未來做好定位的機會,同時以為股東創造更高價值為目標。
R&D increased 10% this quarter, as our sustained focus on innovation has supported us with a meaningful new product pipeline that's as strong today as any time in our history. And I remain encouraged with the progress we're making which has resulted in a number of recent accomplished with that I'd like to briefly highlight this morning. First of all, within our leading hemophilia franchise, we've achieved a number of milestones. As you know, ADVATE was approved in December by the FDA as the only recombinant Factor VIII prophylactic treatment for both children and adults. This approval was based on a study demonstrating that ADVATE significantly reduced median annual bleed rates from 44 bleeds when treated on demand to one when treated prophylactically and included the approval of a new dosing schedule that offers some patients the choice of fewer infusions versus the current standard prophylaxis regimen.
本季研發(R&D)支出增加 10%,我們對創新的持續聚焦,支持我們建立具實質意義的新產品研發管線,其強度不亞於公司歷史上任何時期。我也持續對我們所取得的進展感到鼓舞,這些進展帶來了多項近期成果,我想在今早簡要重點說明。首先,在我們領先的血友病產品線中,我們達成了多項里程碑。如各位所知,ADVATE 已於 12 月獲美國 FDA 核准,成為唯一可用於兒童與成人之重組第八凝血因子(Factor VIII)預防性治療。此核准係基於一項研究,顯示 ADVATE 可將年出血次數中位數由按需治療時的 44 次顯著降低至預防性治療時的 1 次,並同時核准新的給藥時程,讓部分病患可選擇較現行標準預防療程更少的輸注次數。
The initial response from customers has been very as evidenced by the strong double-digit growth of ADVATE in the United States during the first quarter. We remain encouraged regarding the long-term growth prospects of our hemophilia franchise as we've secured both competitive gains and conversions from on-demand therapy to prophylaxis and we'll continue to invest in additional marketing activities to promote our competitive advantage and drive awareness of this expanded label. Also in hemophilia, we announced the initiation of a Phase I clinical trial of BAX 855 a longer acting PEGylated Factor VIII therapy based on the full-length ADVATE model molecule. The Phase I results will serve as the foundation for advancing this important program through clinical development and determining whether BAX 855 can offer a treatment regimen requiring fewer infusions than ADVATE.
客戶的初步反應非常正面,從第一季 ADVATE 在美國呈現強勁的雙位數成長即可見一斑。我們對血友病產品線的長期成長前景仍感到鼓舞,因為我們同時取得競爭性市占提升,以及從按需治療轉換至預防性治療的使用轉換;我們也將持續投入更多行銷活動,以強化競爭優勢並提升對此擴大適應症標籤的認知。同樣在血友病領域,我們宣布啟動 BAX 855 的第一期臨床試驗;BAX 855 為一種長效 PEG 化第八凝血因子療法,係以全長 ADVATE 模型分子為基礎。第一期結果將作為推進此重要計畫進入臨床開發的基礎,並用以判斷 BAX 855 是否能提供較 ADVATE 需要更少輸注次數的治療方案。
In our regenerative medicine business we initiated a Phase III trial to evaluate the efficacy and safety of an individual's own CD34+ stem cells to increase exercise capacity in patients with chronic myocardial ischemia or CMI. CMI is one of the most severe forms of coronary artery disease causing significant long-term damage to the heart muscle and disability to the patient. It's often diagnosed based on symptoms of severe chest discomfort that do not respond to conventional medical management or surgical interventions. In addition, in the quarter we received approval for TISSEEL fibrin sealant for vascular surgery, providing a broad hemostasis label in the United States. This is an expansion beyond previously marketed indications and represents a significant opportunity for this franchise going forward.
在我們的再生醫學業務中,我們啟動第三期試驗,以評估使用個人自體 CD34+ 幹細胞提升慢性心肌缺血(CMI)患者運動能力的有效性與安全性。CMI 是冠狀動脈疾病中最嚴重的型態之一,會對心肌造成顯著的長期損害,並使患者失能。其診斷通常基於嚴重胸部不適等症狀,且對傳統藥物治療或外科介入無反應。此外,本季我們也取得 TISSEEL 纖維蛋白封合劑用於血管手術的核准,使其在美國具備更廣泛的止血適應症標籤。這是對先前上市適應症的擴大,並代表該產品線未來一項重要機會。
In antibody therapies, we filed GAMMAGARD LIQUID for Multifocal Motor Neuropathy or MMN, representing our first neurological indication in the United States. If approved, GAMMAGARD LIQUID will be the first and only licensed immunoglobulin therapy for MMN in the US, where we've been branded orphan drug status by the FDA. This will complement the approval we received last year for MMN in Europe. Also, we initiated a second global Phase III trial evaluating the use of GAMMAGARD LIQUID in treating patients with mild to moderate Alzheimer's disease, following a successful futility analysis that was conducted by the Data Safety Monitoring Board in January. This trial complements our first Phase III trial which is firmly enrolled in looking through conclude by the end of 2012.
在抗體療法方面,我們已就 GAMMAGARD LIQUID 用於多灶性運動神經病變(MMN)提出申請,這將是我們在美國的第一個神經科適應症。若獲核准,GAMMAGARD LIQUID 將成為美國首個且唯一獲許可用於 MMN 的免疫球蛋白療法;該適應症亦已由 FDA 授予孤兒藥資格。這將與我們去年在歐洲取得的 MMN 核准相互呼應。此外,在資料安全監測委員會(Data Safety Monitoring Board)於 1 月完成成功的無效性(futility)分析後,我們啟動第二項全球第三期試驗,評估使用 GAMMAGARD LIQUID 治療輕至中度阿茲海默症患者。此試驗與我們第一項第三期試驗相互補充;第一項試驗已穩健完成收案,並預計於 2012 年底前完成。
We've also announced an extensive study for those patients who completed 18 months of treatment in the first Alzheimer's Phase III trial and meet the required inclusion and exclusion criteria. This study is intended to provide additional data related to longer term safety, efficacy, and pharmacoeconomic impact of immunoglobulin treatment in these patients. These achievements that I just mentioned depict just a handful of the programs in our pipeline that will present great opportunities for Baxter in the years to come and we look forward to updating you on further R&D achievements as the year unfolds.
我們也宣布一項延伸研究,針對在第一項阿茲海默症第三期試驗中完成 18 個月治療且符合所需納入與排除標準的患者。此研究旨在提供與免疫球蛋白治療於這些患者之長期安全性、有效性及藥物經濟學影響相關的額外資料。我剛才提到的這些成果,僅是我們研發管線中少數幾個計畫的縮影;這些計畫將在未來數年為百特帶來重大機會,我們也期待在今年接下來的時間,持續向各位更新更多研發成果。
Before I turn the call over to Bob in just a minute I'd like to comment on the announcements this week regarding HyQ and also the one issue this morning regarding the site selection of our new plasma fractionation facility to support future growth of plasma proteins. First, we remain very positive regarding the long-term growth prospects of our plasma-based specialty therapeutics business, including GAMMAGARD LIQUID, FLEXBUMIN, FEIBA, ARALAST, and GLASSIA. As you know, many of these therapies are used in treating diseases that continue to be both undertreated and underdiagnosed globally. Our continued confidence stems from our global market position, the safety and efficacy profile that our products command and our unique differentiation strategy focused on new delivery options, expanded indications, and broadening access to care in developing markets.
在我稍後把電話交給 Bob 之前,我想就本週關於 HyQ 的公告,以及今早關於我們新建血漿分離製程(plasma fractionation)設施選址、以支持血漿蛋白未來成長的一項議題,做一些說明。首先,我們對以血漿為基礎的專科治療業務之長期成長前景仍非常正面,其中包括 GAMMAGARD LIQUID、FLEXBUMIN、FEIBA、ARALAST 與 GLASSIA。如各位所知,這些療法中有許多用於治療在全球仍普遍存在治療不足與診斷不足的疾病。我們持續的信心來自我們的全球市場地位、產品所具備的安全性與有效性特徵,以及我們獨特的差異化策略:聚焦於新的給藥選項、擴大適應症,以及在開發中市場擴大醫療可近性。
While we are committed to supporting global market demand in the near term, we've selected a site in Covington, Georgia, for a new state-of-the-art plasma fractionation facility to support longer term growth. Construction will begin this year and will include operations supporting plasma fractionation, purification, fill-finish, and a testing lab. Commercial production is scheduled to begin in 2018, with the new fractionation facility adding up to 3 million liters of new capacity annually when fully operational. The investment at the Georgia site is expected to total more than $1 billion over the next five years, and provide us with the flexibility and necessary infrastructure to expand even further in support of additional global market needs.
在我們致力於短期內支持全球市場需求的同時,我們已選定喬治亞州科溫頓(Covington, Georgia)作為新建最先進血漿分離製程設施的基地,以支持更長期的成長。工程將於今年動工,並將包含支援血漿分離、純化、充填與包裝(fill-finish)以及檢測實驗室的營運。商業化生產預計於 2018 年開始;新分離製程設施在全面運轉後,每年可新增最高達 300 萬公升的產能。預期未來五年在喬治亞基地的投資總額將超過 10 億美元,並為我們提供彈性與必要的基礎設施,以進一步擴張並支援更多全球市場需求。
Second, earlier this week as you know, Baxter and Halozyme announced that the FDA has requested additional information to complete its regulatory review of HyQ. The agency is requesting additional data on the use of hyaluronidase for chronic administration, specifically in relation to the HyQ Biologics License Application. Just to be clear, there were no safety concerns cited by the FDA with the respect to immunoglobulin therapy which as you know has a well-established safety profile and has been approved for chronic administration for patients with primary immune deficiencies. Baxter and Halozyme intend to work closely together to further understand FDA's request and develop a plan to provide additional data. In addition we expect to participate in a future meeting of the FDA's Blood Products Advisory Committee to obtain clarification on next steps.
第二,如各位所知,本週稍早 Baxter 與 Halozyme 宣布,FDA 已要求提供額外資訊,以完成其對 HyQ 的法規審查。該機構要求提供關於透明質酸酶(hyaluronidase)用於慢性給藥的額外數據,特別是與 HyQ 生物製劑許可申請(BLA)相關。為了說清楚,FDA 並未就免疫球蛋白治療提出任何安全性疑慮;如各位所知,該療法具有良好且已確立的安全性概況,並已獲核准可供原發性免疫缺陷患者進行慢性給藥。Baxter 與 Halozyme 擬密切合作,以進一步了解 FDA 的要求,並制定提供額外數據的計畫。此外,我們預期將參與 FDA 血液製品諮詢委員會未來的會議,以釐清後續步驟。
In light of this request we now expect a delay in the anticipated regulatory review and approval timeline, which could delay the launch of HyQ beyond 2012. As you know, the change in the anticipated timeline for approval of HyQ is not material, financially material to our 2012 guidance. And of course, as we obtain additional information, we'll continue to update all of you on our plans and expectations. As always, I'd be happy to address any questions you might have on that or other topics during the Q&A this morning, but first I'd like to ask Bob to review our first quarter financial results and also our guidance for 2012. Bob?
鑑於此項要求,我們目前預期原先預估的法規審查與核准時程將延後,這可能使 HyQ 的上市時間延至 2012 年之後。如各位所知,HyQ 預期核准時程的變動,在財務上並不構成對我們 2012 年指引的重大影響。當然,隨著我們取得更多資訊,我們將持續向各位更新我們的計畫與預期。一如往常,我很樂意在今天上午的問答環節中回答各位就此或其他主題可能提出的任何問題;但在此之前,我想請 Bob 回顧我們第一季的財務結果,以及我們對 2012 年的指引。Bob?
- Corporate VP and CFO
- Corporate VP and CFO
Thanks, Bob, and good morning, everyone. As Bob mentioned, earnings per diluted share in the first quarter excluding special items increased 3% to $1.01 per diluted share, which exceeded our guidance range of $0.98 to $1.00. As mentioned in the press release, our GAAP results included a net after-tax benefit from special items totaling $19 million of income or $0.03 per diluted share for costs and adjustments related to recent business development transactions. Specifically, we recorded a special after-tax charge totaling $34 million, or $0.06 per diluted share, primarily related to the upfront cash payment to Momenta for the development and commercialization of biosimilar compounds. This charge was more than offset by a gain of $53 million or $0.09 per diluted share resulting from an adjustment to estimated milestone payments associated with the 2011 Prism Pharmaceuticals acquisition.
謝謝,Bob,各位早安。如 Bob 所提到,第一季在排除特殊項目後的稀釋每股盈餘成長 3%,達到每股 1.01 美元,超出我們 0.98 至 1.00 美元的指引區間。如新聞稿所述,我們的 GAAP 結果包含與近期業務發展交易相關之成本與調整所帶來的特殊項目稅後淨利益,合計 1,900 萬美元的收益,或稀釋每股 0.03 美元。具體而言,我們認列一筆特殊項目稅後費用合計 3,400 萬美元,或稀釋每股 0.06 美元,主要與支付給 Momenta 的一次性預付款現金有關,用於生物相似藥化合物的開發與商業化。該費用被一筆 5,300 萬美元的收益(或稀釋每股 0.09 美元)所抵銷;該收益源自於對 2011 年 Prism Pharmaceuticals 收購案相關之估計里程碑付款的調整。
Now let me briefly walk you through the P&L by line item for the first quarter before turning to our financial outlook for 2012. Starting with sales. Worldwide sales totaled $3.4 billion in the force quarter and increased 3%. Excluding foreign currency, sales increased 4% which exceeded our sales growth guidance of approximately 2%. Better than expected sales materialized in a number of key product categories in both medical products and bioscience, and we also benefited from the Synovis acquisition, which closed earlier than planned. As a reminder, the benefit from recent acquisitions, which includes Synovis and Baxa was partially offset by the divestiture of US multisource generic injectables business. The net benefit of acquisitions and divestitures on sales in the quarter was less than $20 million.
現在,在談到我們 2012 年的財務展望之前,我先按損益表各項目簡要帶各位回顧第一季表現。先從銷售額開始。第一季全球銷售額合計 34 億美元,成長 3%。若排除匯率影響,銷售成長 4%,高於我們約 2% 的銷售成長指引。醫療產品與生物科學的多個關鍵產品類別均出現優於預期的銷售表現;此外,我們也受惠於 Synovis 收購案較原計畫更早完成交割。提醒各位,近期收購(包括 Synovis 與 Baxa)帶來的效益,部分被我們出售美國多來源學名注射劑業務所抵銷。本季收購與處分對銷售的淨貢獻低於 2,000 萬美元。
In terms of individual business performance, beginning with bioscience, global bioscience sales of approximately $1.5 billion increased 4% in the first quarter and excluding foreign currency, sales increased 5%. Within the product categories, recombinant sales rose 4% and totaled $533 million. Excluding foreign currency, sales increased 5% as double-digit growth of 10% in the US was partially offset by the impact of the Australian tender. Excluding the impact of the tender, recombinant sales increased 8%. As Bob mentioned we are very pleased with the strength of our US business, where we are driving benefits associated with the new expanded label of ADVATE.
就各業務表現而言,先從生物科學開始:第一季全球生物科學銷售約 15 億美元,成長 4%;若排除匯率影響,銷售成長 5%。在各產品類別中,重組產品(recombinant)銷售成長 4%,合計 5.33 億美元。若排除匯率影響,銷售成長 5%;其中美國市場達到 10% 的雙位數成長,但部分被澳洲標案(tender)的影響所抵銷。若排除該標案影響,重組產品銷售成長 8%。如 Bob 所提到,我們對美國業務的強勁表現感到非常滿意;我們正推動 ADVATE 新擴大適應症標籤所帶來的效益。
Moving on to plasma proteins, sales in the quarter were $316 million, and increased 3% versus the prior-year period. On a constant currency basis, sales increased 4%. US sales declined 3%, due in part to lower plasma derived Factor VIII sales resulting from the continued convergence to recombinant therapies and lower sales of albumin as we aggressively manage our global supply. This resulted in strong growth in plasma proteins outside the US, driven by double-digit growth of albumin particularly in China and robust demand for FEIBA.
接著談血漿蛋白:本季銷售為 3.16 億美元,較去年同期成長 3%。以固定匯率計算,銷售成長 4%。美國銷售下滑 3%,部分原因是血漿來源第八凝血因子(Factor VIII)銷售下降(因治療持續向重組療法收斂),以及我們積極管理全球供應而導致白蛋白(albumin)銷售降低。因此,美國以外的血漿蛋白呈現強勁成長,主要由白蛋白的雙位數成長(尤其在中國)以及 FEIBA 的強勁需求所帶動。
In antibody therapy sales of $388 million increased 4%. Excluding foreign currency, sales were up 5%, as we continue to experience very strong demand for GAMMAGARD LIQUID, particularly in the US, and we remain well-positioned given our successful launch of our Sub-Q therapy where we continue to seek momentum in share gains given its favorable tolerability profile and low infusion site reaction rate. In addition, as you know, Octapharma returned to the market on a global basis last year. As previously communicated the estimated benefit of the Octapharma impact in the first quarter 2011 was approximately $30 million. Excluding the benefit from the prior year, growth in antibody therapy was 14% on a constant currency basis, significantly higher than estimated market growth, suggesting that we've retained market share on a global basis that was gained during Octa's absence.
在抗體治療方面,銷售 3.88 億美元,成長 4%。若排除匯率影響,銷售成長 5%;我們持續看到 GAMMAGARD LIQUID 的需求非常強勁,特別是在美國。同時,憑藉我們成功推出的皮下(Sub-Q)療法,我們仍具備良好競爭位置;該產品具備良好的耐受性概況與較低的注射部位反應率,我們也持續尋求在市占提升上取得動能。此外,如各位所知,Octapharma 去年已在全球範圍內重返市場。如先前所溝通,估計 Octapharma 影響在 2011 年第一季帶來的效益約為 3,000 萬美元。若排除去年該項效益,抗體治療以固定匯率計算的成長為 14%,顯著高於估計的市場成長,顯示我們在 Octa 缺席期間於全球所取得的市占,已在其回歸後仍得以維持。
In the first quarter, sales in regenerative medicine, which includes our BioSurgery products, totaled $154 million and increased 10%. Excluding foreign currency, sales grew 11% as a result of double-digit growth of FloSeal and the incremental benefit from the Synovis acquisition of just over $10 million. Finally, revenues in the other category totaled $71 million in the quarter and declined 4%. Excluding foreign currency, sales declined 3% as growth of vaccines were offset by lower third-party plasma revenues. In medical products, global sales in the first quarter totaled $1.9 billion reflecting an increase of 3% on both a reported and constant currency basis.
第一季,再生醫學(包含我們的 BioSurgery 產品)銷售合計 1.54 億美元,成長 10%。若排除匯率影響,銷售成長 11%,主要來自 FloSeal 的雙位數成長,以及 Synovis 收購案帶來略高於 1,000 萬美元的增量貢獻。最後,「其他」類別本季營收合計 7,100 萬美元,下滑 4%。若排除匯率影響,銷售下滑 3%;疫苗成長被第三方血漿收入下降所抵銷。在醫療產品方面,第一季全球銷售合計 19 億美元,按報告口徑與固定匯率口徑均成長 3%。
Within the product categories, renal sales totaled $588 million and were comparable to the prior-year period. Excluding foreign currency, sales increased 1%, as US PD growth accelerated to mid-single digits supported by solid patient gains. This momentum was offset by lower HD revenues. IV therapy sales advanced 10% to $472 million. Excluding foreign currency, sales increased to 12% driven by higher demand for IV therapies in the US, strong performance globally of our nutrition franchise, and the benefit of the Baxa acquisition with sales totaling approximately $35 million.
在各產品類別中,腎臟(renal)業務銷售合計 5.88 億美元,與去年同期大致持平。若排除匯率影響,銷售成長 1%;美國腹膜透析(PD)成長加速至中個位數,並由穩健的患者增加所支撐。此一動能被血液透析(HD)收入下降所抵銷。靜脈(IV)治療銷售成長 10% 至 4.72 億美元。若排除匯率影響,銷售成長至 12%,主要由美國對 IV 治療需求增加、我們營養產品線在全球的強勁表現,以及 Baxa 收購案帶來的效益所驅動;其中 Baxa 銷售合計約 3,500 萬美元。
Sales in the global injectables category of $505 million declined 2% on both a reported and constant currency basis. Excluding the net headwind of $30 million from Baxa and the impact of the US multisource generic injectables divestiture, organic growth was in mid-single digits on a constant currency basis. Performance was driven by our pharma partnering and compounding businesses as well as significant growth of certain injectable therapeutics like cyclofosfamide, a generic oncology drug. Infusion systems sales totaled $208 million and declined 1% on both a reported and constant currency basis. This expected decline is a result of lower access set sales as we complete the transition to Spectrum and near completion of the COLLEAGUE consent order.
全球注射劑(injectables)類別銷售 5.05 億美元,按報告口徑與固定匯率口徑均下滑 2%。若排除 Baxa 帶來的 3,000 萬美元淨逆風,以及出售美國多來源學名注射劑業務的影響,有機成長以固定匯率計算為中個位數。表現主要由我們的製藥合作(pharma partnering)與調劑(compounding)業務所帶動,並包括某些注射用治療藥物的顯著成長,例如環磷醯胺(cyclofosfamide),一種學名腫瘤用藥。輸注系統(infusion systems)銷售合計 2.08 億美元,按報告口徑與固定匯率口徑均下滑 1%。這項符合預期的下滑,源自於在我們完成向 Spectrum 的轉換、以及 COLLEAGUE 同意令(consent order)接近完成之際,access set 銷售降低。
Finally, our anesthesia franchise posted robust sales of $138 million, reflecting a 17% increase versus the prior year. Excluding foreign currency, sales were up 18%. While growth was enhanced by easy comparison to the prior year, we did experience very solid demand for both sevoflurane and Suprane on a global basis. This growth in volume more than offset continued pricing pressures for generic sevoflurane. Turning to the rest of the P&L, gross margin for the Company was 50.8%, in line with our expectations, and lower than last year's gross margin by 20 basis points. Margin expansion resulting from mixed benefits was more than offset by headwinds, including incremental pension expense, austerity measures, and dilution from business development transactions.
最後,我們的麻醉產品事業群繳出強勁銷售額1.38億美元,較去年同期成長17%。若排除外幣影響,銷售成長18%。雖然成長受惠於去年同期較低的比較基期,但我們確實在全球範圍內看到七氟醚(sevoflurane)與 Suprane 的需求非常穩健。銷量成長已足以抵銷學名藥七氟醚持續的價格壓力。接著看損益表其餘項目,公司毛利率為50.8%,符合我們的預期,且較去年毛利率低20個基點。產品組合帶來的毛利率擴張效益,已被多項逆風因素所抵銷,包括新增的退休金費用、撙節措施,以及業務開發交易造成的稀釋影響。
SG&A totaled $743 million in the quarter, and increased 4% versus the prior-year period, as a result of incremental pension expense, promotional and marketing expenses, and investments we're making to enhance our global presence particularly in emerging and developing markets. These investments were partially offset by business optimization savings and aggressive management of discretionary spending. R&D spending accelerated 10% to $236 million as we continue to fund and advance a number of late-stage programs including investments in our leading hemophilia franchise, Alzheimer's programs, and our Phase III adult stem cell trial.
本季銷售、一般及行政費用(SG&A)合計7.43億美元,較去年同期增加4%,主要因新增退休金費用、推廣與行銷費用,以及我們為強化全球布局(特別是在新興與開發中市場)所進行的投資。上述投資部分被業務優化節省與對非必要支出的嚴格控管所抵銷。研發支出加速成長10%至2.36億美元,因我們持續投入並推進多項後期計畫,包括對我們領先的血友病事業群、阿茲海默症計畫,以及第三期成人幹細胞試驗的投資。
The operating margin in the quarter was 21.9%, 80 basis points below prior year, due to a lower gross margin and higher SG&A and R&D that's expected to enhance future sales growth and profitability. Interest expense was $18 million compared to $10 million last year. This increase can be attributed to interest expense associated with a $500 million debt issuance in December of last year and lower interest income. Other income totaled $4 million in the quarter, compared to expense of $11 million last year, driven primarily by the impact of foreign currency. The tax rate was 21.7% in the quarter, which is higher than our prior-year due to a change in our earnings mix and slightly higher than our full-year expectation. And finally, as previously mentioned, adjusted EPS was $1.01 per diluted share an increase of 3%.
本季營業利益率為21.9%,較去年低80個基點,原因在於毛利率較低,以及較高的SG&A與研發支出;這些支出預期將提升未來的銷售成長與獲利能力。利息費用為1,800萬美元,去年為1,000萬美元。此增加主要歸因於去年12月發行5億美元債務所產生的利息費用,以及利息收入下降。本季其他收益合計400萬美元,去年同期為1,100萬美元的費用,主要受外幣影響所致。本季稅率為21.7%,因獲利組合變化而高於去年,且略高於我們對全年稅率的預期。最後,如先前所提,調整後每股盈餘(EPS)為稀釋後每股1.01美元,成長3%。
Turning to cash flow, cash flow from operations in the fourth quarter totaled $413 million, and increased 11% versus last year. Capital expenditures totaled $239 million which compares to $198 million in the first quarter 2011. DSO ended the quarter at 58 days, an increase of two days versus the prior year, entirely due to an increase in international days outstanding. And inventory turns of 2.3 were essentially unchanged from the first quarter last year. And lastly, during the first quarter, we repurchased approximately 10 million shares of common stock for $575 million or on a net basis approximately 7 million shares for $421 million, on track to achieve our full year objective of net share repurchases totaling approximately $1 billion.
接著看現金流,第四季營運活動現金流合計4.13億美元,較去年增加11%。資本支出合計2.39億美元,對比2011年第一季的1.98億美元。應收帳款週轉天數(DSO)季末為58天,較去年增加2天,完全是因國際應收帳款天數增加所致。存貨週轉率2.3次,與去年第一季基本持平。最後,在第一季期間,我們以5.75億美元回購約1,000萬股普通股;或以淨額計算,以4.21億美元回購約700萬股,進度符合我們全年淨回購約10億美元的目標。
Finally, let me conclude my comments this morning by providing our financial outlook for the second quarter and full year 2012. First, for the full year, we have narrowed our guidance range and now expect earnings of $4.49 to $4.57 per diluted share. By line item of the P&L, starting with sales, we continue to project full-year sales growth excluding foreign currency of 4% to 5%. Given our current outlook for foreign exchange rates, we expect currency to negatively impact the top line by 2 percentage points. Therefore, we respect reported sales growth which excludes the impact of foreign currency to be in the 2% to 3% range. We continue to expect full-year gross margin rate for the Company to be flat to modestly below the 2011 gross margin of 51.4%.
最後,讓我以提供我們對2012年第二季與全年財務展望來結束今天上午的評論。首先,就全年而言,我們已縮窄指引區間,現預期稀釋後每股盈餘為4.49至4.57美元。按損益表各項目來看,先從銷售額開始,我們仍預估排除外幣影響的全年銷售成長為4%至5%。依我們目前對匯率的展望,預期匯率將使營收(top line)受到約2個百分點的負面影響。因此,我們預期以報表口徑呈現、且排除外幣影響後的銷售成長將落在2%至3%的區間。我們仍預期公司全年毛利率將與2011年51.4%的毛利率持平或小幅低於該水準。
We expect SG&A and R&D to grow in low to mid-single digits. Interest expense is expected to total approximately $80 million and other expense excluding noncontrolling interest will be in the $20 million to $30 million range. We assume a tax rate of approximately 21.5%, flat with 2011, and now expect a full-year average share count of approximately $555 million which assumes approximately $1 billion in net share repurchases. From a cash flow perspective we plan to generate cash flow from operations of more than $3 billion, which includes an outflow of approximately $250 million related to the finalization of the COLLEAGUE consent order.
我們預期SG&A與研發支出將以低至中個位數百分比成長。利息費用預期合計約8,000萬美元;其他費用(不含非控制權益)預期落在2,000萬至3,000萬美元區間。我們假設稅率約21.5%,與2011年持平;並預期全年平均流通股數約為5.55億股,該假設包含約10億美元的淨股票回購。就現金流角度而言,我們計畫產生超過30億美元的營運活動現金流,其中包含約2.5億美元的現金流出,與完成 COLLEAGUE 同意令(consent order)相關。
Now to expand on full-year sales assumptions for each of the businesses. First, on a constant currency basis, we continue to expect medical product sales to grow in the mid-single digits. This includes IV therapy sales growth of approximately 10%, which includes the benefit of approximately $120 million in sales related to the Baxa acquisition. Anesthesia sales growth in high single digits reflecting the strong performance in the first quarter. Global injectable sales growth in mid-single digits, which includes the net benefit of Baxa sales totaling approximately $40 million and the divestiture impact of approximately $60 million. Infusion systems sales which are expected to decline approximately 5% and reflect a tough comparison for SIGMA as we complete the consent order later this year. And lastly, renal sales growth is expected to be in low single digits.
接下來進一步說明各事業的全年銷售假設。首先,以固定匯率(constant currency)計算,我們仍預期醫療產品銷售將以中個位數百分比成長。其中包含靜脈輸注治療(IV therapy)銷售約10%的成長,並包含因收購 Baxa 帶來約1.2億美元的銷售貢獻。麻醉產品銷售預期為高個位數成長,反映第一季的強勁表現。全球注射劑銷售預期為中個位數成長,其中包含 Baxa 銷售淨貢獻約4,000萬美元,以及處分(divestiture)影響約6,000萬美元。輸注系統銷售預期下滑約5%,並反映 SIGMA 的艱難比較基期,因我們將於今年稍晚完成同意令。最後,腎臟相關銷售成長預期為低個位數。
For bioscience, we project sales growth excluding foreign currency in the mid-single digits, and there's no change to our original guidance by product category. Our outlook includes recombinant sales growth in low single digits reflecting the impact of recent tenders, plasma protein sales growth in mid-single digits, antibody therapy sales growth in low single digits which includes robust underlying demand in the impact from Octapharma. I'd like to take just a moment to point out that in the second quarter we face our most difficult year-on-year comparison, for antibody therapy and as sales increased 21% on a constant currency basis. And as you know, we expect to continue and improve our inventory position in advance of our third-quarter shutdown of the old LA fractionation facility. Therefore, our expectations it include an assumption that global antibody therapy sales will be lower in Q2 this year versus the prior-year period.
在生物科學方面,我們預估排除外幣影響的銷售成長為中個位數百分比,且各產品類別的原始指引不變。我們的展望包含:重組產品(recombinant)銷售低個位數成長,反映近期標案(tenders)的影響;血漿蛋白(plasma protein)銷售中個位數成長;抗體治療(antibody therapy)銷售低個位數成長,其中包含強勁的基本需求以及來自 Octapharma 的影響。我想花點時間指出,第二季我們將面臨抗體治療最艱難的年對年比較,因去年第二季在固定匯率基礎下銷售成長達21%。此外,如各位所知,我們預期將在第三季關閉舊的洛杉磯(LA)分離(fractionation)工廠之前,持續並改善我們的庫存水位。因此,我們的預期包含一項假設:今年第二季全球抗體治療銷售將低於去年同期。
Moving onto regenerative medicine, we expect sales growth of approximately 20% which includes incremental sales from Synovis of approximately $75 million. And finally the other category is expected to decline approximately 5%. As mentioned in our press release, for the second quarter, we expect earnings per diluted share of $1.10 to $1.12 and sales growth excluding the impact of foreign currency of approximately 3% to 4%. Based on our outlook for foreign exchange rates, we expect currency to impact sales by approximately 3 percentage points. Therefore we expect reported sales to grow in the 0% to 1% range. Thanks and now I'd like to open up the call for Q&A.
再來看再生醫學,我們預期銷售成長約20%,其中包含 Synovis 帶來約7,500萬美元的新增銷售。最後,其他類別預期下滑約5%。如我們新聞稿所述,第二季我們預期稀釋後每股盈餘為1.10至1.12美元,且排除外幣影響的銷售成長約為3%至4%。依我們對匯率的展望,預期匯率將使銷售受到約3個百分點的影響。因此,我們預期報表口徑的銷售成長將落在0%至1%區間。謝謝,接下來我想開放問答。
Operator
Operator
(Operator Instructions)
(接線員指示)
I would like to remind participants that this call is being recorded and a replay will be available on the Baxter International website for 30 days at www.baxter.com. David Lewis, Morgan Stanley.
提醒各位與會者,本次電話會議將被錄音,並可於 Baxter International 網站 www.baxter.com 取得重播,為期30天。David Lewis,Morgan Stanley。
- Analyst
- Analyst
This is actually James in for David. My first question is on the new capacity plant in Georgia. Couple points there. One, I think given the 3 million liter capacity total spend in CapEx of a $1 billion dollars is a little bit more than we are expecting. Could you give any details on whether that also includes additional purification capacity and is that -- would that be able to -- could you expand that capacity beyond 3 million liters with the infrastructure you're putting in place? Second, 3 million liters actually seems a little bit less than we were expecting to meet your capacity needs over the long term. Can you talk a little bit about your ability to bridge to that new facility with the existing capacity at the old and new LA facilities?
其實我是 James,代替 David 來提問。我的第一個問題是關於喬治亞州的新產能工廠。這裡有幾點。第一,我認為以 300 萬公升的產能來看,總資本支出(CapEx)達 10 億美元,似乎比我們預期的要高一些。你們能否提供一些細節,說明這是否也包含額外的純化產能?以及在你們正在建置的基礎設施下,是否能將產能擴充到超過 300 萬公升?第二,300 萬公升看起來其實比我們預期的要少一些,可能不足以滿足你們長期的產能需求。你們能否談談在新設施投產前,如何利用洛杉磯舊廠與新廠的既有產能來銜接過渡?
- Chairman, CEO
- Chairman, CEO
Yes, James, this is Bob Parkinson. Let me maybe kind of address your question at a higher level and then I'm going to turn it over to Bob Hombach to take you through some of the elements of the CapEx spending that we projected. First of all, just to back up a bit, if you look at our current plans, with old LA putting it back in commission, as well as some expansion opportunities at new LA, Vienna and Rieti, we certainly feel that our installed footprint of capacity to support 6% to 8% kind of growth over the next few years setting the stage then longer-term for the capacity expansion that we announced this morning.
是的,James,我是 Bob Parkinson。我先從較高層次回應你的問題,接著我會把時間交給 Bob Hombach,請他帶你了解我們所預估的資本支出中的一些要素。首先,先稍微回顧一下,如果你看我們目前的計畫,包括讓洛杉磯舊廠重新投入運作,以及在洛杉磯新廠、維也納與 Rieti 的一些擴產機會,我們確實認為,現有已建置的產能版圖足以支撐未來幾年約 6% 到 8% 的成長,並為我們今天早上宣布的長期產能擴張奠定基礎。
I would say the announcement this morning first of all is an expression I think represents our confidence in the long-term global growth of the plasma protein business. A little bit of context -- over half of the world's population remains undiagnosed and certainly undertreated for many of the conditions that are treated today with therapeutic proteins, and being the world leader in this area, the announcement this morning is really an investment for the long-term and speaks to our confidence in the business. As Bob will explain to you in a minute, the magnitude of the investment represents more than the initial phase of 3 million liters but sets the stage for the kind of expansion over time that supports the kind of vision that I just described. So with that as context, Bob, I'll let you maybe get a little bit more detail in terms of break out. Okay?
我會說,今天早上的宣布,首先是一種表態,代表我們對血漿蛋白業務長期全球成長的信心。補充一些背景——全球有超過一半的人口仍未被診斷,且對於目前可用治療性蛋白所治療的許多疾病,顯然仍治療不足;而我們作為此領域的全球領導者,今天早上的宣布其實是著眼長期的投資,也反映我們對這項業務的信心。如 Bob 等一下會向你說明,這項投資的規模不僅涵蓋初期 300 萬公升的階段,也為未來隨時間推進的擴張奠定基礎,以支撐我剛才描述的願景。在這樣的背景下,Bob,我讓你再提供一些更細的拆解說明。好嗎?
- Corporate VP and CFO
- Corporate VP and CFO
Sure. In terms of capacity and investments in capacity, historically, you've seen us bolt on additional capacity expansions onto existing footprint and I think others in the industry. This announcement today represents a true Greenfield site where we are going to be putting infrastructure in place in addition to and we were very careful to point this out in the press release, it is fractionation capacity, it is purification capacity, it is fill-finish capacity, and an additional testing lab which is another requirement in the overall plasma fractionation process that we need to have in place. So we are adding all elements in one location here, whereas historically you may have heard additional capacity investments talked about in a piecemeal fashion. As we look at this investment, approximately 30% of this investment place to infrastructure and as Bob just mentioned, that infrastructure will support both this initial 3 million in capacity but also significantly more capacity in the future. And by making the investment now, it will position us to add that additional capacity in the future at a lower marginal cost and in a much more timely fashion than this Greenfield site is going to take for us to bring up.
當然。就產能與產能投資而言,過去你們看到我們(以及我想業界其他公司)多半是在既有版圖上以「加掛」方式進行額外的擴產。今天的宣布代表一個真正的綠地(Greenfield)基地;我們將在此建置基礎設施,並且——我們在新聞稿中特別謹慎地指出——這包含分餾(fractionation)產能、純化(purification)產能、充填與包裝(fill-finish)產能,以及一個額外的檢測實驗室;而檢測實驗室也是整體血漿分餾流程中我們必須具備的另一項要求。因此,我們是在同一地點一次性加入所有要素;而過去你可能聽到的產能投資,往往是以零散、分段的方式來談。就這項投資來看,約有 30% 用於基礎設施;如 Bob 剛才提到,這些基礎設施不僅支援初期 300 萬的產能,也能在未來支援顯著更高的產能。而現在就先行投資,將使我們未來新增產能時具備更低的邊際成本,並且能以更及時的方式擴充,相較於要把這個綠地基地從零建置到可運作所需的時間。
- Chairman, CEO
- Chairman, CEO
Does that answer your question?
這樣有回答到你的問題嗎?
- Analyst
- Analyst
No. That absolutely addresses my question. Very helpful. Thanks. The second question is just on recombinant. Obviously very strong growth in the US this quarter. I was wondering do you think that represents true -- presumably, that's growing faster than market, that 10% figure. I think that represents more patient share gains and that patients are switching to ADVATE. Or does it represent higher dosing and maybe a little bit more use of prophylaxis among your existing patients?
有。這完全回答了我的問題。非常有幫助。謝謝。第二個問題是關於重組產品(recombinant)。很明顯你們本季在美國的成長非常強勁。我想問,你們認為這是否代表真正的——推測應該是比市場更快的成長,也就是那個 10% 的數字。我認為這可能代表更多病患市占的提升、病患轉用 ADVATE。或者這是否反映更高的用量(dosing),以及你們既有病患中預防性治療(prophylaxis)使用增加?
- Chairman, CEO
- Chairman, CEO
I'm not sure at this stage we know. I think that it probably represents some of each of those elements that you just described, James. So I think it's too early to be able to quantify which of those variables is the most pronounced. But we know specifically that on a patient-by-patient basis that we are gaining conversions. One from competition and then two, expansion and use of ADVATE given the broader label. So as we stated in our prepared comments, early start but it's quite encouraging.
現階段我不確定我們是否已經知道。我想它可能同時包含你剛才提到的各個因素,James。所以現在要量化哪一個變數最為顯著,還太早。但我們明確知道,就逐一病患來看,我們確實正在取得轉換(conversions)。第一是從競品轉換過來;第二則是因為標籤適應症更廣,ADVATE 的使用擴大與滲透提升。因此如同我們在事先準備的發言中所說,雖然是早期起步,但相當令人鼓舞。
- Analyst
- Analyst
Thanks. And maybe I can just get one more in on Sub-Q. Even if HyQ is a little bit delayed, I think one of the things that's interesting is that your non- HyQ Sub-Q product has been doing a little bit better than we expected. Would you be able to quantify either from a share or dollar perspective what the run rate there is now?
謝謝。另外我想再問一個關於皮下(Sub-Q)的問題。即使 HyQ 有些延遲,我覺得有趣的一點是,你們非 HyQ 的 Sub-Q 產品表現比我們預期的要好一些。你們能否從市占或金額的角度,量化一下目前的年化/運行水準(run rate)大概是多少?
- Chairman, CEO
- Chairman, CEO
Well, probably I think too early to quantify. Again, as we commented previously and I would reiterate today, James, we're very encouraged by the market response of our 10% Sub-Q as you know, our Sub-Q has the lowest reported local site reaction of any of the Sub-Q products by far. And that's being really validated through the use in the marketplace. Beyond that quantitatively, Mary Kay, I don't know if there's anything you want to share that might be helpful.
嗯,我想可能還太早,難以量化。同樣地,正如我們先前評論過、我今天也會再重申的,James,我們對 10% Sub-Q 的市場反應非常受到鼓舞;如你所知,我們的 Sub-Q 在所有 Sub-Q 產品中,通報的注射部位局部反應最低,且明顯低於其他產品。而這點正透過市場上的實際使用被充分驗證。至於更進一步的量化數字,Mary Kay,我不確定你是否有任何可以分享、可能對他有幫助的資訊。
- Corporate VP, IR
- Corporate VP, IR
Yes. I think we're off to a great start with Sub-Q. We continue to see patient gains both competitively as well as conversions from IV to Sub-Q, James, and our assumption currently include sales approaching on a global basis, because we do also have a product in Europe that we sell of about $100 million in 2012.
有。我認為 Sub-Q 的起步非常好。我們持續看到病患數的增加,既包括競爭性地取得病患,也包括從靜脈注射(IV)轉換到皮下(Sub-Q)的轉換,James;而我們目前的假設包含:在全球範圍內的銷售額將接近——因為我們在歐洲也有一個產品在銷售——2012 年約 1 億美元。
- Chairman, CEO
- Chairman, CEO
And I appreciate your question. Obviously, we'll talk more about this I'm sure with follow-on questions about the HyQ program, the delay and so forth. But your point's a good one, because the reality is with the 10% Sub-Q, we've got a great product, we've got something to promote, we're getting traction in the marketplace. And so growth in this segment is not exclusively dependent on the short-term of the timing approval for HyQ. So that's an important point for everyone to understand.
也謝謝你的提問。很顯然,關於 HyQ 計畫、延遲等等,我們之後一定會在後續問題中談得更多。但你的觀點很好,因為事實是:就 10% Sub-Q 而言,我們有一個很好的產品,也有可推廣的重點,並且正在市場上取得動能。因此,這個區隔的成長並不完全取決於短期內 HyQ 核准時點的進度。所以這是大家需要理解的一個重要點。
- Analyst
- Analyst
Great. Thanks, guys.
很好。謝謝各位。
Operator
Operator
Kristen Stewart, Deutsche Bank.
Kristen Stewart,德意志銀行。
- Analyst
- Analyst
I guess I will follow-up on just kind of any more specifics that you might have on HyQ maybe just helping us frame what your initial expectations are with the FDA's request and maybe some broad timelines, if you can?
我想我會追問一下 HyQ 的部分:你們是否能提供更具體的資訊,協助我們理解 FDA 的要求下,你們最初的預期是什麼,以及如果可以的話,一些大致的時間表?
- Chairman, CEO
- Chairman, CEO
I don't know if we can define the timelines, Kristen. And there is still -- we're still engaged with the discussion with the FDA, so I don't think we want to be premature. I'll ask Dr. Riedel -- Norbert, why don't you comment on this situation, see if you can provide some help to Kristen.
Kristen,我不確定我們能否界定時間表。而且目前仍然——我們仍在與 FDA 進行討論,所以我想我們不希望過早下結論。我請 Dr. Riedel——Norbert,你來評論一下這個情況,看看能否給 Kristen 一些協助。
- Corporate VP, Chief Science and Innovation Officer
- Corporate VP, Chief Science and Innovation Officer
Maybe just as a follow-up to what we have announced at the beginning of the week and to just ground everyone, the study we have done in the administration of immunoglobulin therapies for Hylenex or HyQ is a study where patients were treated with immunoglobulins for more than a year in the extension that we have ongoing actually some patients are approaching three years and we have not seen any serious or nonserious adverse events that would have actually given us any concerns in the clinical study. We have actually talked about the result as recently as last month, where we presented the longer-term studies. And the concerns of the agency are really around the long-term chronic use of the hyaluronidase that is part of this therapy in the administration of immunoglobulin. Immunoglobulin therapy, as you know, from our indication in PID, is indicated for long-term chronic use. So the concerns that the agency has raised our around hyaluronidase in long-term use. I can't really give you a lot of specifics or more specifics than what we have shared, only because we are in dialogue with Halozyme and the FDA as to how to address the concern and what kinds of studies we would propose to address those concerns, but I will of course keep you posted on that as soon as I have a clearer picture and better definition. That's really all I can share with you at this point.
也許作為對我們在本週初所宣布事項的補充,並讓大家回到同一基準,我們針對 Hylenex 或 HyQ 之免疫球蛋白治療給藥所做的研究,是一項在延伸期中讓病患接受免疫球蛋白治療超過一年的研究;事實上,有些病患已接近三年,而我們在該臨床研究中並未看到任何嚴重或非嚴重的不良事件,會讓我們產生任何疑慮。我們其實就在上個月才談到這些結果,當時我們發表了較長期的研究。而主管機關的疑慮,主要在於此療法中用於免疫球蛋白給藥的一部分——透明質酸酶——的長期慢性使用。如各位所知,免疫球蛋白治療,依我們在 PID 的適應症,是用於長期慢性使用。因此,主管機關提出的疑慮是關於透明質酸酶的長期使用。我無法提供太多細節或比我們已分享的更多內容,原因是我們正與 Halozyme 及 FDA 進行對話,討論如何回應該疑慮,以及我們將提出哪些研究來解決這些疑慮;但一旦我有更清楚的圖像與更明確的定義,我當然會立即向各位更新。目前我能分享的就只有這些。
- Analyst
- Analyst
Okay. And then I guess your expectation is to go before a panel. Should I read into it that that seems at least to be positive in that I would imagine you would be able to get some of this data from the extended study? So I guess how should we think about the panel just in terms of possibly helping maybe to support an approval?
好的。那我想你們的預期是會在委員會前審查。我是否可以解讀為,這至少是正面的,因為我想你們應該能從延伸研究中取得部分資料?所以,我們應該如何看待這個委員會審查,就其可能有助於支持核准而言?
- Corporate VP, Chief Science and Innovation Officer
- Corporate VP, Chief Science and Innovation Officer
So the Blood Products Advisory Committee is the panel that you're referring to. It will actually be involved in looking at the proposed studies that we will put forward as to how to address the concerns of the agency. So I think you're right; I think that's a positive. And actually is also really a pretty normal course of action in regular panel, so there's nothing particularly unusual about it. And that's the current plan, that we will actually have a panel, and discuss the study design with the panel.
所以你指的是血液製品諮詢委員會(Blood Products Advisory Committee)。它實際上會參與審視我們將提出的研究方案,以說明如何回應主管機關的疑慮。所以我想你說得對;我認為這是正面的。而且這其實也是一般委員會審查中相當正常的流程,因此並沒有特別不尋常之處。目前的計畫是,我們確實會召開委員會,並與委員會討論研究設計。
- Analyst
- Analyst
Okay. Thank you. Can I ask one other question on the gross margin? Given the recombinant strength in the quarter, I was a little surprised that we didn't see a little bit more upside there. Can you just walk through in any granular detail the moving parts there?
好的。謝謝。我可以再問一個關於毛利率的問題嗎?考量到本季重組產品(recombinant)的強勁表現,我有點意外毛利率沒有看到更多上行。你能否以較細的層次說明一下其中的變動因素?
- Corporate VP and CFO
- Corporate VP and CFO
Yes. What I would say is first and foremost, Q1 is always the lowest quarter from a margin standpoint for us. And most cases. So again, this was in line with our expectation. There were some positive mix benefits as we mentioned. There are some headwinds built into 2012 that we've talked about quite a bit. As we mentioned, we remain very confident in the full-year guidance of flat to very modestly down, which implies that the gross margin will increase in subsequent quarters. I'd also highlight -- the one aspect of seasonality that's pretty consistent in our results is Q2 tends to be a higher margin quarter for us, primarily due to the fact that we have sales in Europe of our FSME vaccine for tick-borne encephalitis and so that's a high-margin products that tends to augment the Q2 margin. So we're certainly expecting margin to improve as we move throughout the year with Q2 again likely to be the highest of the quarters. And again, very comfortable with the full-year guidance.
可以。我首先要說的是,從毛利率角度來看,第一季對我們而言一向是最低的季度。在大多數情況下都是如此。所以再次強調,這符合我們的預期。如我們提到的,產品組合確實帶來了一些正面的效益。2012 年也存在一些我們已談過不少的逆風因素。如我們所提到的,我們仍對全年指引(持平至小幅下滑)非常有信心,這也意味著後續季度的毛利率將會上升。我也想強調——我們結果中一個相當一致的季節性因素是,第二季通常是我們毛利率較高的季度,主要因為我們在歐洲有 FSME 蜱傳腦炎疫苗的銷售,而那是高毛利產品,往往會拉升第二季的毛利率。因此,我們確實預期隨著年度推進毛利率會改善,而第二季很可能仍會是各季度中最高的。再次強調,我們對全年指引非常有把握。
- Analyst
- Analyst
Okay. Thank you.
好的。謝謝。
- Chairman, CEO
- Chairman, CEO
Thanks Kristen.
謝謝,Kristen。
Operator
Operator
David Roman, Goldman Sachs.
David Roman,高盛。
- Analyst
- Analyst
I was hoping you could comment just on HyQ and the extent to which the FDA review, how that influences the international approval timelines and what the latest thinking was there?
我希望你能評論一下 HyQ,以及 FDA 的審查在多大程度上會影響國際核准時程;目前最新的看法是什麼?
- Corporate VP, Chief Science and Innovation Officer
- Corporate VP, Chief Science and Innovation Officer
So as you know, we have actually submitted our dossier in Europe and in Canada as well. It's under review there. And we are in dialogue with those agencies but there's really nothing in particular specific that I need to comment or can comment on because it's an ongoing review process, and it's taking, likewise, it's normal course of action at this point.
如你所知,我們其實已在歐洲以及加拿大提交了申請資料(dossier)。目前正在那邊審查中。我們也正與那些主管機關保持對話,但因為審查仍在進行中,沒有什麼特別具體需要評論或我能評論的;就目前而言,這同樣是正常的審查流程。
- Analyst
- Analyst
Okay. And maybe a follow up on the CapEx questions. For Bob, the $1 billion, how should we think about that getting layered into cash flow statement? Is that something that you're swapping out existing CapEx for that or is that a true net addition of $1 billion spread evenly over the next several years?
好的。再追問一下資本支出(CapEx)問題。Bob,這 10 億美元應該如何在現金流量表中呈現?這是用來替換既有的資本支出,還是說這是真正新增的 10 億美元,並在未來幾年平均分攤?
- Chairman, CEO
- Chairman, CEO
No. That is incremental. In the sense that we always invest in our plasma footprint, and as we've mentioned, we've got additional capacity coming online in Italy as an example. So there's an existing base of expense was a spending that's going on even today. Given the nature of bringing a new plant up though, the spending tends to be a bit more front loaded because you need to get the facility in place, the equipment place, build a conformance lot, submit stability studies, and all of those things.
不是。那是增量(incremental)的。因為我們一向都會投資於我們的血漿版圖(plasma footprint);如我們提到的,例如義大利就有額外產能即將上線。因此,即使在今天也有一個既有的費用基礎與支出正在進行。不過,鑑於新廠啟用的性質,支出往往會較為前置,因為你需要先把設施到位、設備到位、建立符合規範的批次(conformance lot)、提交安定性研究(stability studies),以及所有這些事項。
So I would say 2013 and 2014 are going to be the peak years and from an incremental standpoint of where we're sitting today, I think about it in kind of $400 million of incremental spend in each of those years with some flex between '13 and '14 to accommodate this additional spending. But, what I would add is given our strong cash position, our strong cash flow that we expect to have going forward, our very strong balance sheet and flexibility within our current credit ratings, this additional investment is not going to constrain our ability to continue to do the things we've been doing, which is reinvesting in other parts of our business, returning significant value to shareholders in dividends and buyback and doing select bolt-on acquisitions that augment our portfolio.
所以我會說 2013 年與 2014 年將是高峰年度;以相對於我們目前狀態的增量角度來看,我會把它想成這兩年各約 4 億美元的增量支出,並在 2013 與 2014 年之間保留一些彈性以因應這些額外支出。但我還要補充的是,考量到我們強勁的現金部位、我們預期未來將持續有強勁的現金流、我們非常強健的資產負債表,以及在現有信用評等下的彈性,這項額外投資不會限制我們持續進行我們一直在做的事情:也就是再投資於業務的其他部分、透過股利與庫藏股回購向股東回饋可觀價值,以及進行選擇性的補強型併購(bolt-on acquisitions)以擴充我們的產品組合。
- Analyst
- Analyst
Okay. That's helpful. And then lastly, maybe, Bob Parkinson you could provide some context for the acceleration in R&D spend. This has been a pretty consistent theme at Baxter certainly since you've been there. I think R&D spending is up over 50% since you joined the Company. Maybe the HyQ disappointment on Monday, I think, does raise some questions about the return profile of some of that R&D. Can you talk just how we should think about the return on that investment and when we start to see a little bit more top and bottom line contribution from those investments that you've made?
好的。這很有幫助。最後,或許 Bob Parkinson 你能就研發支出加速提供一些背景。這在 Baxter 一直是相當一致的主題,至少自你到任以來是如此。我想自你加入公司以來,研發支出已增加超過 50%。也許週一 HyQ 的失望消息,確實引發了一些對於部分研發投資報酬輪廓的疑問。你能談談我們應該如何看待這些投資的報酬,以及何時會開始在營收與獲利(top and bottom line)上看到更多貢獻嗎?
- Chairman, CEO
- Chairman, CEO
Well, first of all, I don't think anyone should associate the disappointment and the delay in HyQ with the broader pipeline. In my prepared comments this morning I cited just a few examples of many in terms of how we're progressing in all of our businesses on multiple fronts. The ramp up in R&D since I've been here as we've discussed many times is a reflection of, at the end of the day what's our most important strategic priority, which is the ability to innovate, because that's really the only sustainable business model in this industry in my view. Again as I've commented, a number of times, I tried to be as objective about this as I can.
嗯,首先,我不認為任何人應該把 HyQ 的失望與延遲,與更廣泛的產品線研發管線(pipeline)連結在一起。在我今天早上準備好的發言中,我只舉了眾多例子中的幾個,說明我們在所有業務上、在多個面向的進展。自我在這裡以來研發的提升,如我們多次討論過的,反映了——歸根究柢——我們最重要的策略優先事項是什麼:也就是創新能力,因為以我之見,那才是這個產業唯一可持續的商業模式。再次如我多次評論過的,我已盡可能客觀地看待這件事。
I really believe our pipeline today is the strongest that it's been in the history of the Company. The profile of what's in our pipeline, are largely products that are higher margin than the overall Company. Clearly that represents a better growth trajectory with primary focus on core franchises, hemophilia, being one, renal and dialysis being another, and so forth. So in terms of the impact, obviously we all know HyQ was the near-term opportunity to have some material effect on our sales growth. But I mean, things that we've already got approved and launched from the 10% Sub-Q we talked about the expanded label on ADVATE.
我確實相信,我們目前的研發管線是公司歷史上最強的一次。我們管線中的產品組合輪廓,大多是毛利率高於公司整體平均的產品。顯然,這代表更佳的成長軌跡,主要聚焦於核心產品線/核心事業群,例如血友病是一個,腎臟與透析是另一個,等等。因此就影響而言,顯然我們都知道 HyQ 是短期內有機會對我們銷售成長產生實質影響的項目。但我的意思是,我們已經獲准並上市的項目,包括我們談到的 10% 皮下(Sub-Q)以及 ADVATE 的擴大適應症標籤。
Sometimes we don't typically associate with these with R&D spend but these are all programs that required R&D investment and the highest payback and the most significant return are on those things that further enhance the position of franchises or businesses that are already established. As just a couple of examples, we hope to get the approval on the MMN indication. So I'll stop short of playing back the entire pipeline, but let's not associate the shorter-term disappointment on HyQ as a reflection of the broader pipeline, because the strategic priority is as I described.
有時候我們不會典型地把這些和研發支出聯想在一起,但這些都是需要研發投資的計畫;而最高的回報與最顯著的投資報酬,往往來自於那些能進一步強化既有且已建立之產品線或事業地位的項目。舉兩個例子,我們希望能取得 MMN 適應症的核准。所以我就不把整個管線逐一重述了,但不要把 HyQ 的短期失望視為對更廣泛管線的反映,因為策略優先順序如我所描述。
- Analyst
- Analyst
Okay. That's very helpful context. Thank you.
好的。這些背景非常有幫助。謝謝。
Operator
Operator
Mike Weinstein, JPMorgan Chase & Co.
Mike Weinstein,摩根大通(JPMorgan Chase & Co.)。
- Analyst
- Analyst
Bob, maybe I can ask a question on HyQ because I do want to focus on it. And I think there are probably two questions. I think the first question is, what does Halozyme have available in terms of its data set, both clinical and nonclinical, that you think could be of value of the FDA that the FDA has not already seen? And second, this response by the FDA certainly surprised the Company. This is an issue we discussed over the last couple of years, the FDA's comfort with the chronic usage of hyaluronidase. So why do you think this surprised the Company and what was missing in the back-and-forth of the FDA that had this come out last-minute?
Bob,也許我可以就 HyQ 問個問題,因為我確實想聚焦在它上面。我想大概有兩個問題。第一個問題是,Halozyme 在其資料集方面(臨床與非臨床)有哪些你認為可能對 FDA 有價值、但 FDA 可能尚未看過的資料?第二,FDA 的這個回覆確實讓公司感到意外。這是我們過去幾年討論過的議題,也就是 FDA 對透明質酸酶(hyaluronidase)長期慢性使用的接受度。那麼你認為為什麼公司會感到意外?以及在與 FDA 的往返溝通中,缺少了什麼,才會讓這件事在最後一刻才浮現?
- Chairman, CEO
- Chairman, CEO
Well, look, the one thing we all know is it's difficult to speculate on the motivation or rationale of the FDA. I think it is fair to say that we were surprised, certainly disappointed. Norbert, I'm going to have you address the first part of the terms of Halozyme data, what do we have and so on, recognizing that we're limited in talking about it until we get further down the path in our dialog with the agency.
嗯,你看,我們都知道的一件事是,很難去揣測 FDA 的動機或理由。我想可以公平地說,我們感到意外,當然也很失望。Norbert,我請你回應第一部分,關於 Halozyme 的資料、我們有哪些等等;也要理解在我們與主管機關的對話更往前推進之前,我們能談的內容有限。
- Corporate VP, Chief Science and Innovation Officer
- Corporate VP, Chief Science and Innovation Officer
Mike, we have talked about this before, you and I have talked about this before, I was very much focused on the actual clinical trial results that we saw in our Phase III trial with Hylenex in PID. And as I mentioned in my earlier comments, we have seen a very clean efficacy and safety profile in that study, not only within the Phase III that was submitted to the agency but also with respect to the extension that we have ongoing where patients have been on therapy for almost three years now. So clearly I have and continue to have a high level of confidence that the clinical trial data is very strong data and we published that and you referred to that in your write-up.
Mike,我們之前談過這個,你和我之前談過;我非常聚焦在我們在 PID 的 Hylenex 第三期試驗中看到的實際臨床試驗結果。如同我在先前評論中提到的,我們在該研究中看到非常乾淨的療效與安全性輪廓,不僅是在提交給主管機關的第三期資料中,也包括我們目前仍在進行的延伸試驗;到現在病人接受治療已將近三年。因此我很明確地一直、也仍然對臨床試驗資料的強度抱持高度信心;我們也已發表這些資料,而你在你的報告中也有引用。
With respect to the agencies concerned, it's really about introducing the recombinant human PH20, or hyaluronidase, as a long-term chronic administration of a molecule and questions or concerns around that. We are truly working with Halozyme on a daily basis to identify what data exists and what data the agency's looking for and how to best design studies around those data. At this point, that's really all I can tell you. And as soon as we have that better defined, we will of course communicate that. But that's the current status.
就主管機關的疑慮而言,重點其實在於將重組人類 PH20(也就是透明質酸酶)作為一種分子進行長期慢性給藥,以及圍繞這點所產生的問題或擔憂。我們確實每天都與 Halozyme 合作,釐清有哪些既有資料、主管機關在尋找哪些資料,以及如何圍繞這些資料來最佳化設計研究。目前我能告訴你的大概就只有這些。一旦我們把這些定義得更清楚,當然會對外溝通。但目前狀態就是如此。
- Analyst
- Analyst
Bob, does the potential push out of Halozyme, I'm not talking about six months but of HyQ, the push out maybe beyond six months making this a longer push out, does that potential change your thinking at all on M&A in terms of appetite not only for the -- you've talked about wanting to do a series of smaller deals but potentially doing anything larger?
Bob,Halozyme(我不是指六個月,而是指 HyQ)可能被往後推遲、甚至超過六個月、變成更長的延後,這種可能性會不會在併購(M&A)方面改變你的想法?不只是你談過想做一系列較小的交易,也包括是否可能做更大型的交易?
- Chairman, CEO
- Chairman, CEO
No. It doesn't. Our priorities in terms of M&A are consistent with what we see -- I don't see any correlation between the two at all is the straight-out answer to it.
不會。不會改變。我們在併購方面的優先順序,與我們所看到的情況一致——我完全看不出兩者之間有任何關聯,這就是直接的答案。
- Analyst
- Analyst
Understood. I think the question from the Street would be, if the targets you have internally for reaccelerating revenue growth, and a lot of that is going to be driven by the pipeline, if those targets get pushed out, would that lead you to pursue M&A more aggressively, or sooner than you would have otherwise? That's the thinking behind it.
了解。我想華爾街的問題會是:如果你們內部設定的、用來讓營收成長重新加速的目標,而其中很大一部分將由研發管線驅動;如果那些目標被往後推遲,是否會讓你更積極、或更早去推動併購?這是背後的思路。
- Chairman, CEO
- Chairman, CEO
I don't think so. I think our outlook and obviously we look forward to getting together with everybody at the Investor Conference in October to talk about this. I mean, let's just back up and put this in perspective. We're disappointed in the delay of HyQ. Only a handful of analysts, I think yourself included, Mike, had even quantified what the long-term impact was or longer-term impact. I think the average incremental revenue associated with this in 2014, so in other words two years post-launch was somewhere between $100 million and $200 million. I don't want to minimize that. That's not insignificant but in the context of a company of our size, particularly, just to be very candid with you in view of the reaction of the market this week, is a total disconnect, okay?
我不這麼認為。我想我們的展望——而且我們也期待在十月的投資人會議與大家聚在一起談這些。我的意思是,讓我們退一步,把這件事放在正確的脈絡下。我們對 HyQ 的延遲感到失望。但只有少數分析師——我想包括你在內,Mike——曾量化其長期影響或較長期影響。我認為與此相關、在 2014 年(也就是上市後兩年)的平均增量營收,大約落在 1 億到 2 億美元之間。我不想淡化這點。這不是小數目,但以我們這種規模的公司來看,尤其坦白說,從本週市場的反應來看,這完全是脫節的,好嗎?
And the other point I would make is, assuming this represents just a delay, as you all know, because we talk about fractionation capacity all the time, the incremental value of HyQ was more price-related than it was volume-related, because to be very candid, with the 10% Sub-Q which I commented robust market growth, opportunities globally, we can sell as much IVIG as we can make, independent of whether we have HyQ approved or not. So again I don't want to minimize the incremental value primarily associated with the price but if the composite or consensus average of incremental sales two years out was somewhere between $100 million and $200 million, that puts you in a quantitative perspective, vis-a-vis the reaction to the markets this week. So you know what? I'll just leave it at that.
我還要補充一點:假設這只是延遲,如各位所知,因為我們一直在談分離(fractionation)產能,HyQ 的增量價值更多是來自價格,而不是來自銷量;因為坦白說,憑藉我所評論的 10% 皮下(Sub-Q)所帶來的強勁市場成長、以及全球機會,我們能賣出多少 IVIG 取決於我們能生產多少,與 HyQ 是否獲准無關。所以我再次強調,我不想淡化主要來自價格的增量價值;但如果兩年後的增量銷售之綜合或共識平均值約在 1 億到 2 億美元之間,這就能讓你用量化角度來看待本週市場反應。所以你知道嗎?我就說到這裡。
- Analyst
- Analyst
No. I think that was perfect. Let me ask you a couple other pipeline follow-ups.
不。我覺得那樣非常到位。我再問你幾個關於管線的追問。
- Chairman, CEO
- Chairman, CEO
Sure.
當然。
- Analyst
- Analyst
One, can you just talk about ADVATE approval in China? Is that coming as well as from other emerging markets I know you're waiting on? And second, where are you on timeline for filing your recombinant Factor IX product?
第一,你能否談談 ADVATE 在中國的核准?那是否也會到來,以及我知道你們也在等待的其他新興市場的進展?第二,你們的重組第 IX 因子(recombinant Factor IX)產品申報時程目前到哪一步了?
- Chairman, CEO
- Chairman, CEO
Okay. Well, the ADVATE approval -- Mary Kay help me here. Russia and China are still on track for this year.
好的。嗯,ADVATE 的核准——Mary Kay,這裡幫我一下。俄羅斯和中國今年仍按計畫進行。
- Corporate VP, IR
- Corporate VP, IR
On track, Mike. Second half of this year. No change at this point to our expectation for both China and Russia. And in regards to the recombinant Factor IX, we are looking -- that's also on track to be completed here and filed in the second half as well.
進度如期,Mike。今年下半年。目前我們對中國與俄羅斯的預期沒有改變。至於重組第IX因子,我們正在推進——該項目也按計畫進行,預計同樣在下半年完成並提交申請。
- Analyst
- Analyst
Perfect. Thank you, guys.
太好了。謝謝各位。
Operator
Operator
Matt Miksic, Piper Jaffray & Co.
Matt Miksic,Piper Jaffray & Co.。
- Analyst
- Analyst
Not to beat a dead horse here on your points you just made, Bob, on HyQ, but I do want to be clear about one thing, and I think you talked about this in the past. Let's say hypothetically it was going to be $100 million or $200 million product in two years. Is it also fair to say that you're thinking was you get into the Sub-Q market with Sub-Q and then you add to that, drive mix, drive some incremental share possibly? But to some degree, penetrate your Sub-Q business over time with HyQ?
我不想在你剛才提到的 HyQ 觀點上老調重彈,Bob,但我想把一件事講清楚,我記得你過去也談過。假設在兩年後它可能會成為一個 1 億或 2 億美元的產品。那麼是否也可以說,你的想法是先用 Sub-Q 進入皮下(Sub-Q)市場,然後在此基礎上再加碼,推動產品組合、帶來一些增量市占?但在某種程度上,HyQ 也會隨時間逐步滲透你們既有的 Sub-Q 業務?
- Chairman, CEO
- Chairman, CEO
Yes. Clearly that was the original strategy. And it still is based on the timing of the approval of HyQ. I think the difference is originally when we launched the 10% Sub-Q, we saw it as a catch-up to be then competitive, with other Sub-Qs on the market. In other words a catch-up wants to set the stage for HyQ. What we've learned as I've commented, we have the superior Sub-Q product right now which has a lot more traction and opportunity than what we had earlier anticipated. So the strategy remains the same, to overtime upgrade to HyQ when and if we get approval for HyQ, but in the meantime we have more upside and opportunity on 10% than what we had estimated at the start. If that makes sense to you.
是的。很明顯那是最初的策略。而且就 HyQ 的核准時點而言,現在仍然如此。我認為差別在於,最初我們推出 10% Sub-Q 時,把它視為一個追趕產品,讓我們能與市面上其他 Sub-Q 產品競爭。換句話說,這個追趕是為 HyQ 鋪路。但我們學到的是——如我先前所說——我們目前的 Sub-Q 產品更具優勢,獲得的動能與機會也比我們先前預期的更大。因此策略仍相同:隨時間推進,在我們取得 HyQ 核准時(若取得)逐步升級到 HyQ;但在此期間,10% 產品的上行空間與機會比我們一開始估計的更大。希望你能理解。
- Analyst
- Analyst
It does. So there, I'd look at that $100 million to $200 million number and I'd say, well part of that was an overlay on existing business at that time. So I would agree with your earlier comments and those were very helpful. One point if I could on what the FDA has said or focused on in terms of the chronic use. You mentioned I think clearly that there is no safety concerns for IVIG, which is used chronically and widely. Was there any observations or any blip in the data that the FDA has seen or focused on for hyaluronidase? Or is this a matter of routine that they've just decided to be more careful?
理解。所以我看那個 1 億到 2 億美元的數字,會認為其中一部分是在當時既有業務之上的疊加。因此我同意你先前的評論,那些非常有幫助。我想再問一點:關於 FDA 對慢性使用所說或關注的部分。你提到很清楚,IVIG 長期且廣泛使用,沒有安全性疑慮。那麼對於透明質酸酶(hyaluronidase),FDA 是否在數據中看到或特別關注到任何觀察結果或小波動?還是說這只是例行作法,他們只是決定要更謹慎?
- Chairman, CEO
- Chairman, CEO
I'll ask Norbert to comment on that.
我請 Norbert 來評論一下。
- Corporate VP, Chief Science and Innovation Officer
- Corporate VP, Chief Science and Innovation Officer
Maybe I'll expand on it in the following way. There was nothing in particular. I think it has to do with, in a reasonable way, has to do with the recombinant hyaluronidase being positioned for chronic long-term use for which it is currently not indicated. And I think the questions and concerns are all around that aspect of this therapy. And keep in mind maybe as a follow-up to the earlier questions, while our Sub-Q is positioning us extremely well in the space of [this cloud of] administration, we have always looked at the HyQ as truly a transformational, game-changing, incremental improvement, much beyond what Sub-Q does.
我可以用以下方式補充說明。沒有任何特別的問題。我認為這合理地與重組透明質酸酶被定位為慢性、長期使用有關,而目前它並沒有這樣的適應症。我想問題與疑慮都圍繞在這項治療的這個面向。另外,作為對先前問題的延伸,雖然我們的 Sub-Q 讓我們在[這一雲端的]給藥領域中處於非常有利的位置,但我們一直把 HyQ 視為真正具轉型意義、改變遊戲規則的增量改善,遠超過 Sub-Q 所能帶來的。
So it's one of those pioneering programs in our pipeline that we think are highly promising but also in a way go down a new path with the regulators. And therefore, there's a little bit more uncertainty than there would be in a Factor IX or Factor VII or a [vonvillipon] Factor which is a more straightforward, maybe a lifecycle management product development approach versus pioneering new ground. And that also speaks to the pipeline being really balanced between lifecycle management opportunities that are truly enhancing existing core businesses and new opportunities like HyQ, like stem cells, for which I think we need to make resources available because that is our legacy of truly bringing first-to-market innovations to our patients and customers. But to draw conclusions from HyQ in general onto the pipe and the productivity of the pipeline I think will be really misplaced.
因此它是我們研發管線中那種開創性的專案之一:我們認為非常有前景,但同時也在某種程度上與監管機構走上一條新路。因此,相較於第IX因子、第VII因子或[vonvillipon] 因子這類較為直接、可能屬於產品生命週期管理的開發方式,開拓新領域的不確定性會更高一些。這也說明我們的管線在兩者之間取得了很好的平衡:一方面是生命週期管理機會,確實能強化既有核心業務;另一方面是像 HyQ、像幹細胞這樣的新機會,我認為我們需要配置資源,因為這正是我們的傳統——為病患與客戶帶來首創上市的創新。但若從 HyQ 的情況去推論整體管線與管線生產力,我認為會是非常不恰當的。
- Analyst
- Analyst
That's very helpful. And then one if I could just on, Bob, your comments on I think holding share obtained from Octa last year was sort of the math that you were doing with the $30 million benefit that you saw in the first quarter of '11, when does that -- you sort of have given if I recall correctly, your guidance assumes that you'd surrender something like $100 million of gained share last year back to Octapharma as they got into the market. It doesn't seem like that's happening yet from the numbers the your reporting, because when does that turn into potentially edging up some of the expectations for the year?
這非常有幫助。另外我想再問一個:Bob,你提到去年從 Octa 那裡取得的市占要能守住,你在做的計算似乎是 2011 年第一季看到的 3,000 萬美元效益;那麼這個效益何時會——如果我沒記錯,你們的指引假設會把去年取得的大約 1 億美元市占,隨著 Octapharma 重返市場而交還回去。但從你們目前公布的數字看起來似乎還沒發生;那麼這何時可能轉化為上調今年預期的可能性?
- Corporate VP and CFO
- Corporate VP and CFO
Well, a couple things. As we pointed out in our prepared comments, we are going to have a tough comp in the second quarter. But we will see stronger growth in the third or fourth quarter. But as we also mentioned, because of shutting down the old facility extending its useful life and providing important flexibility going forward, we are going to be constrained this year. We have shifted product to meet market needs, and so I didn't want to imply here that specific customer by customer retention of share from Octa because different price points, different geographies where they're stronger and so on. But in aggregate, stepping back and looking at the level of demand we're seeing for our product, again augmented here with the strong uptake for 10% Sub-Q in the Sub-Q market, we feel very good about how our share position overall has evolved and we have not competed to try to retain some of those more price sensitive customers that we've talked about before that are likely targets for Octa's reentry.
嗯,有幾點。如同我們在事先準備的發言中指出的,第二季的比較基期會很硬。但我們會在第三或第四季看到更強的成長。不過我們也提到,因為關閉舊廠、延長其使用年限並在未來提供重要的彈性,我們今年的供應會受到限制。我們已調整產品配置以滿足市場需求,因此我不想在此暗示是針對某個特定客戶逐一保留從 Octa 取得的市占,因為不同的價格帶、不同的地理區域他們較強等等因素。但整體而言,退一步看我們產品目前看到的需求水準,再加上 10% Sub-Q 在皮下市場的強勁導入,我們對整體市占地位的演變感到非常樂觀;而且我們並未為了保留那些我們之前談過、對價格更敏感、可能成為 Octa 重返市場目標的客戶而去競爭。
- Analyst
- Analyst
Okay. That's helpful. Thanks so much for taking the questions.
好的。這很有幫助。非常感謝回答問題。
- Corporate VP, IR
- Corporate VP, IR
Thanks, Matt.
謝謝,Matt。
Operator
Operator
Rajeev Jashani, UBS.
Rajeev Jashani,UBS。
- Analyst
- Analyst
Just on the recombinants business, there's obviously pretty robust result there in the US. And I was just wondering if you could help us understand what we can expect there, maybe in the US and ex-US across the remainder of the year. One quarter obviously was very strong, but can we expect the same kind of growth across the balance of the year and maybe ex-US declines widening? Or if you could throw out any other color there. Thanks.
關於重組產品業務,美國那邊顯然有相當強勁的表現。我想請你們協助我們理解,今年剩餘期間在美國以及美國以外市場,我們可以期待什麼。單一季度當然非常強,但我們能否期待今年其餘時間也有同樣類型的成長?以及美國以外市場的下滑是否會擴大?或是你們能否提供任何其他補充說明。謝謝。
- Corporate VP and CFO
- Corporate VP and CFO
Recall that we're in the process of the Australian tender playing out, so we're going to have tough comps throughout the course of this year on the international front, related to the Australian tender, which is going to murk up the picture here as we go forward. Again, we're very encouraged by first-quarter results in the US, and the reaction from both treaters and patients to the very strong data from the ADVATE label expansion, and prophy indication for adults, and so on. But again, it's early days, so I would say we expect to be in good position to grow at least with the market here in the US throughout the course of this year but again, we're going to have tough comps internationally and that's reflected in our global guidance for the full year.
請記得我們正處於澳洲標案進行的過程中,因此在國際市場方面,今年整年我們都會面臨較硬的比較基期,這與澳洲標案有關,未來會讓整體情況看起來更不清晰。再說一次,我們對第一季在美國的結果非常受到鼓舞,治療端與病患端對 ADVATE 標籤擴增的強勁數據、成人預防性(prophy)適應症等的反應也非常正面。但目前仍是早期階段,因此我會說,我們預期今年在美國至少能跟隨市場成長;不過國際市場仍會面臨較硬的比較基期,這也反映在我們對全年全球的指引之中。
- Analyst
- Analyst
Great. And I had one follow-up on the IVIG market. I think there was a pretty healthy increase reported in the CMS database for pricing for the fourth quarter. And I was just wondering if you could comment whether you saw that sustained over the first quarter? Thanks.
很好。我還有一個關於 IVIG 市場的追問。我記得 CMS 資料庫顯示第四季的定價有相當健康的上升。我只是想請你們評論一下,第一季是否也看到這樣的趨勢持續?謝謝。
- Corporate VP and CFO
- Corporate VP and CFO
No. We've got to be careful here, because as you know, there's a number of dynamics that come into play with CMS reporting. We've talked about the fact in terms of the contracting process here for 2012 with our customers in the US, we had a very modest price increase, certainly well below 6%. And so that has to do with timing and how we report certain adjustments and rebates and following their rules and so on, so I would not attribute much value to that 6%, because that is not what we're seeing.
沒有。我們在這裡必須小心,因為如你所知,CMS 的申報會受到多種動態因素影響。我們談過,針對 2012 年在美國與客戶的簽約流程,我們只有非常溫和的價格上調,確實遠低於 6%。因此那與時點、以及我們如何依其規則申報某些調整與回扣等有關,所以我不會把那個 6% 看得太重要,因為那不是我們所看到的情況。
- Analyst
- Analyst
Thanks so much.
非常感謝。
- Chairman, CEO
- Chairman, CEO
Mary Kay, would you follow-on to the first part of the question?
Mary Kay,你要接著回答問題的第一部分嗎?
- Corporate VP, IR
- Corporate VP, IR
I was just going to add, Rajeev, that in recombinants, as Bob mentioned, we didn't change our full-year guidance at this point. The Australian impact is about $60 million for the full year, and as that will play out over the course of the year. We'll have a little bit easier comp outside the US as we get into the back half of the year. But just an example of the impact Australia has had, international sales were flat in the quarter, including the impact of Australia and ex that, they were up 6% in line generally with the market growth that we're seeing and estimating.
我只是想補充一下,Rajeev,就重組產品而言,如 Bob 提到的,我們目前沒有調整全年指引。澳洲的影響全年約為 6,000 萬美元,而且會在一年當中逐步反映。當我們進入下半年時,美國以外的比較基期會稍微容易一些。不過舉例來說,澳洲的影響之下,本季國際銷售持平;若排除澳洲影響,則成長 6%,大致符合我們所看到並估計的市場成長。
- Analyst
- Analyst
Thank you very much.
非常感謝。
Operator
Operator
Bob Hopkins, Bank of America Merrill Lynch.
美國銀行美林(Bank of America Merrill Lynch)的 Bob Hopkins。
- Analyst
- Analyst
Sorry to add another Bob to the call here. (laughter) So first on HyQ, I assume the FDA has seen the data approaching three years that you mentioned in your comments earlier?
抱歉,這通電話又多了一位 Bob。(笑聲) 首先關於 HyQ,我假設 FDA 已經看過你先前評論中提到、接近三年的資料?
- Corporate VP, Chief Science and Innovation Officer
- Corporate VP, Chief Science and Innovation Officer
No. The answer is no, we have not yet submitted the data on the extension study to the FDA.
沒有。答案是沒有,我們尚未把延伸研究的資料提交給 FDA。
- Analyst
- Analyst
And how many patients are out beyond 1 year at this point? How many patients do you have that are out to that three-year mark?
那目前有多少病患已經超過 1 年?有多少病患已經到達三年的那個時間點?
- Corporate VP, Chief Science and Innovation Officer
- Corporate VP, Chief Science and Innovation Officer
It's just a few more than 50 patient that continue in the extension study, and recall the Phase III study itself was just trial of 90 patients. I think it was 87. So 56 I believe are continuing in the extension study.
延伸研究中持續參與的病患只有 50 多位;而且請記得第三期研究本身只有 90 位病患,我想是 87 位。我相信目前有 56 位持續在延伸研究中。
- Analyst
- Analyst
So the data obviously they've seen the one-year data on all patients so you're going to at some point present to them the incremental data here. I'm just trying to frame the timing. I know there's not much you can say on this, but listening to the conversation you're talking about designing new studies and questions about chronic use. It would seem to me that we should really be thinking about this in terms of an 18-month delay, at least. From your perspective, is there a better scenario here that's possible from a timing perspective? Or is the 18 months that I'm using as a placeholder probably not a bad way of thinking about it at this point?
所以他們顯然已經看過所有病患的一年期資料,而你們之後某個時間點會把新增的資料提供給他們。我只是想掌握一下時程。我知道你們對此能說的不多,但聽你們的對話,你們在談設計新的研究,以及關於慢性使用的問題。在我看來,我們至少應該把這件事視為延後 18 個月。從你們的角度,時程上是否有可能出現更好的情境?或者我用 18 個月作為暫時的假設,在目前階段其實也不算太差的思考方式?
- Corporate VP, Chief Science and Innovation Officer
- Corporate VP, Chief Science and Innovation Officer
Truly, I don't know what's actually leads you to the 18 months that you are using. I can only tell you that at this stage, I really can't put a clear timeframe around it, because that all depends on, not only the design of the studies, but also the discussion with the FDA and with the advisory committee, so it's truly too early. But I do believe that we will be pushed out beyond 2012. As I get closer to understanding what exactly needs to be done, than I can help you with the timeline. But at this point it would be speculating and I'd rather not do that.
老實說,我不確定你為什麼會用 18 個月這個數字。我只能說,在這個階段我真的無法給出明確的時間表,因為那不僅取決於研究設計,也取決於與 FDA 以及諮詢委員會的討論,所以現在確實還太早。但我確實相信會延到 2012 年之後。等我更接近了解到底需要做什麼之後,我就能協助你釐清時程。但目前這樣說只是猜測,我寧可不這麼做。
- Analyst
- Analyst
Okay. And then a question on plasma capacity. Your guidance for this year is for basically low to mid-single digit growth in those businesses. At what point do your capacity constrains ease? And one way to ask a question is if we look out beyond 2012, if the demand were there, could you grow those plasma businesses more in that 6% to 8% type of area as we think about 2013, again, if the demand were there? I'm just trying to get a sense as when you think these capacity constraints will ease and is thinking about high single-digits possible beyond 2012 if the demand warrants it?
好的。接著問一個關於血漿產能的問題。你們今年的指引基本上是這些業務低到中個位數的成長。你們的產能限制在什麼時候會緩解?換個方式問,如果我們看 2012 年之後,假設需求存在,到了 2013 年你們是否能把血漿相關業務的成長拉高到 6% 到 8% 這樣的區間?我只是想了解你們認為這些產能限制何時會緩解,以及若需求支持,2012 年之後是否有可能做到高個位數成長?
- Chairman, CEO
- Chairman, CEO
This is what I tried to comment on at the outset is with keeping old LA in the commission and some of the other expansion initiatives we have, we believe our install capacity can support growth over the next few years, let's say in the 6% to 8% range, Bob.
這就是我一開始試著評論的:透過讓舊 LA 持續運轉,以及我們其他一些擴產計畫,我們相信已安裝的產能可以支撐未來幾年的成長,比方說在 6% 到 8% 的區間,Bob。
- Corporate VP, IR
- Corporate VP, IR
That's volume growth.
那是量的成長。
- Chairman, CEO
- Chairman, CEO
That's volume growth.
那是量的成長。
- Analyst
- Analyst
Okay. So when specifically do the capacity constraints start to ease? Is that really not until kind of the beginning of 2013?
好的。那具體來說,產能限制什麼時候開始緩解?是不是要到 2013 年初左右才會?
- Corporate VP and CFO
- Corporate VP and CFO
Yes. I would say kind of towards the middle of 2013, because that's what we've talked about. We're taking old LA down for five months towards the end of this year but with the plasma production cycles that you're familiar with of up to six months it's going to take into the second quarter before we've got it back up, running and go through the process and have sellable product. So I would put it as kind of middle of next year before that's online. But as we also have mentioned we're bringing additional capacity onto the back half of this year in our Rieti, Italy facility. We are ramping up production this year and continue to ramp up the utilization level in new LA. We'll take another step up in early 2013 as well. So that will alleviate some of the pressure here, but I think really to be in the most robust situation, it's middle of 2013.
是的。我會說大概在 2013 年年中左右,因為我們一直是這麼談的。我們會在今年底前後讓舊 LA 停機五個月,但以你熟悉的血漿生產週期(最長可達六個月)來看,要到第二季才會恢復運轉、完成流程並產出可銷售的產品。所以我會把它定位為明年年中左右才會上線。不過如我們也提過的,我們在義大利 Rieti 廠會在今年下半年導入額外產能。我們今年會逐步拉升產量,並持續提高新 LA 的產能利用率。我們也會在 2013 年初再往上提升一個台階。因此這會緩解部分壓力,但我認為要到最穩健的狀態,會是在 2013 年年中。
- Chairman, CEO
- Chairman, CEO
But the 6% to 8% over the next few years is reasonable and that's IGs, really.
但未來幾年 6% 到 8% 是合理的,而且那主要是 IG。
- Corporate VP and CFO
- Corporate VP and CFO
Yes. That's IGs, really.
是的。主要是 IG。
- Chairman, CEO
- Chairman, CEO
Albumin would have --
白蛋白會——
- Corporate VP and CFO
- Corporate VP and CFO
Others, we would be in better shape.
其他品項我們的狀況會更好。
- Chairman, CEO
- Chairman, CEO
We'd be in better shape on albumin.
白蛋白方面我們會更有餘裕。
- Analyst
- Analyst
That's perfect. Thanks very much.
太好了。非常感謝。
- Chairman, CEO
- Chairman, CEO
You bet.
不客氣。
Operator
Operator
Rick Wise, Leerink Swann.
Leerink Swann 的 Rick Wise。
- Analyst
- Analyst
Just a couple things and I apologize I jumped on a little bit late. Did you review any update on the home hemo product timing and when you're expecting to get that product launched and going?
我只有幾點,抱歉我稍微晚了一點才加入。你們是否有更新居家血液透析(home hemo)產品的時程,以及預計何時推出並開始推動?
- Chairman, CEO
- Chairman, CEO
Actually, we did not, Rick. It's a timely question. Norbert or Mary Kay, you want to give the specifics?
其實我們沒有,Rick。這個問題問得很及時。Norbert 或 Mary Kay,你們要不要提供具體細節?
- Corporate VP, Chief Science and Innovation Officer
- Corporate VP, Chief Science and Innovation Officer
So the study is actually ongoing, the clinical study and I would characterize it as patients on therapy really liking the therapy. So since we restarted, we have had no issues to deal with and therefore, our projected timeline remains for a CE marking in Europe in 2013 and for US launch in 2014. As US filing in 2014, I'm sorry.
因此,這項研究其實仍在進行中,也就是臨床研究;我會將其描述為接受治療的病患非常喜歡這項療法。因此,自從我們重新啟動以來,沒有遇到任何需要處理的問題,所以我們的預期時程仍維持:2013 年在歐洲取得 CE 認證,並於 2014 年在美國上市。美國申報在 2014 年,抱歉。
- Analyst
- Analyst
So filing, US filing in 2014?
所以,申報,美國申報在 2014 年?
- Corporate VP, Chief Science and Innovation Officer
- Corporate VP, Chief Science and Innovation Officer
Correct.
正確。
- Analyst
- Analyst
And that would take another -- assume the things went normally, that might take another year so it's 2015 if all goes well for a launch, theoretically?
那還需要再花一年——假設一切進展正常,可能還要再一年,所以如果一切順利,理論上是 2015 年上市?
- Corporate VP, Chief Science and Innovation Officer
- Corporate VP, Chief Science and Innovation Officer
It shouldn't take that long, because -- I'd rather not speculate on it, so let's stay with filing and then see what happens thereafter.
不應該需要那麼久,因為——我寧可不對此臆測,所以我們就先以申報為準,之後再看後續進展。
- Analyst
- Analyst
Okay.
好的。
- Corporate VP and CFO
- Corporate VP and CFO
Rick, as we've mentioned in the past, we're as excited about the opportunities for home HD outside the US as we are inside. While we would love to have an approval in the US as soon as possible, we certainly can make a lot of headway on this program by getting a CE mark and moving forward in those markets where today we have a well-established PD business. There is a well accepted approach to home treatment for dialysis in Europe and reimbursement rates are attractive.
Rick,如同我們過去提到的,我們對於美國以外居家 HD 的機會,和美國境內一樣感到興奮。雖然我們希望能盡快在美國取得核准,但我們當然也可以透過取得 CE 認證,在目前我們已建立完善 PD 業務的市場推進,讓這個計畫取得很大進展。在歐洲,對透析居家治療有一套廣為接受的做法,而且給付水準也很具吸引力。
- Chairman, CEO
- Chairman, CEO
We still have 80% of our renal businesses, PD business outside of the US. So sometimes people lose sight of that, so that's really the big opportunity in the short-term.
我們的腎臟業務中,仍有 80% 的 PD 業務在美國以外。所以有時候大家會忽略這點,而這在短期內其實是最大的機會。
- Analyst
- Analyst
Right. Thanks. Just two more questions and I'll let you pick and choose if you've discussed it before. Just an update on the integration of med delivery in renal. It sounds like we're pretty much done and Bob Hombach, I'd be curious to hear is to if there's further cost cutting beyond that. And last, Norbert, any update on the Alzheimer's program and Phase III data and next reported milestones? Anything would be appreciated. Thank you.
了解。謝謝。再兩個問題我就不占用時間了;如果你們之前談過,也可以自行選擇回答。想請更新一下腎臟事業中醫療配送(med delivery)整合的進度。聽起來我們幾乎完成了;Bob Hombach,我也想了解在那之後是否還有進一步的成本削減空間。最後,Norbert,阿茲海默症計畫有沒有更新?第三期數據以及下一個將公布的里程碑?任何資訊都很感謝。謝謝。
- Corporate VP and CFO
- Corporate VP and CFO
Okay. So on the medical products integration front, the way we characterize it up to this point, this is a $75 million to $100 million cost opportunity for us over time. We're probably 2/3 or more down the track of realizing that, but there still are additional leverage opportunities in front of us over the next couple of years. But the lion's share that we have already baked into our expectations.
好的。關於醫療產品整合這一塊,到目前為止我們的說法是:長期而言,這對我們是一個 7,500 萬到 1 億美元的成本機會。我們大概已經走完了 2/3 或更多的實現進度,但未來幾年仍有額外的槓桿機會可挖掘。不過最大的一部分,我們已經納入我們的預期之中。
- Corporate VP, Chief Science and Innovation Officer
- Corporate VP, Chief Science and Innovation Officer
And, Rick, on Alzheimer's, the first Phase III trial, as you know, will complete with the last patient out at the end of this year. And we still expect to have the data analyzed and available in the first half of 2013. The second trial which we initiated after the futility analysis turned out to be positive, has begun to enroll patients, sites have been initiated, so we are off to a good start on the second Phase III trial.
Rick,至於阿茲海默症,如你所知,第一個第三期試驗將在今年年底完成最後一位病患退出(last patient out)。我們仍預期在 2013 年上半年完成數據分析並取得結果。第二個試驗是在無效性(futility)分析結果轉為正向之後啟動的,目前已開始收案,研究中心也已啟動,所以第二個第三期試驗的開局相當順利。
- Analyst
- Analyst
And data presentations interim? Anything coming up the next 6 to 12 months, Norbert?
那中期的數據發表呢?接下來 6 到 12 個月有什麼要公布的嗎,Norbert?
- Corporate VP, Chief Science and Innovation Officer
- Corporate VP, Chief Science and Innovation Officer
No. I don't think so.
沒有。我想沒有。
- Analyst
- Analyst
Okay. Thank you.
好的。謝謝。
- Corporate VP and CFO
- Corporate VP and CFO
Thanks Rick.
謝謝你,Rick。
Operator
Operator
Matthew Dodds, Citigroup.
Citigroup 的 Matthew Dodds。
- Analyst
- Analyst
Couple questions. On the new facility for plasma, is it going to be similar to LA? Because I'm just wondering why you might not want to try to tweak it a bit and see if you can get a little bit more yield out of IG.
兩個問題。關於新的血漿設施,會和洛杉磯(LA)的類似嗎?因為我在想,為什麼你們不想稍微調整一下,看看能不能讓 IG 的產出率再提高一點?
- Chairman, CEO
- Chairman, CEO
Actually, the layout, Matt, we're going to take a little different approach, more of a modular approach than we took at LA. I think that that does several things for us. One is I think relative to the yield question you asked, perhaps do a better job in terms of yield. It also allows us to scale up beyond the 3 million liter incremental capacity that we cited this morning in a quicker fashion if we choose to do that. So the approach is actually quite different than what we took at LA.
其實在配置上,Matt,我們會採取和 LA 略有不同的做法,比起 LA 更偏向模組化的方式。我認為這對我們有幾個好處。第一,就你問的產出率問題而言,或許能在提升產出率方面做得更好。此外,如果我們選擇這麼做,它也讓我們能以更快的速度把我們今天早上提到的 300 萬公升增量產能再往上擴充。所以這個做法其實和我們在 LA 採取的方式相當不同。
- Analyst
- Analyst
And then one final question on renal. Internationally, it grew I think about 1% and it looked like it was off a pretty easy comp. Was there anything unique that happened that quarter, what is it PD, HD, anything you can give color on that?
最後一個關於腎臟業務的問題。國際市場成長我記得大概是 1%,而且看起來比較基期也相對容易。那一季有沒有發生什麼特殊情況?是 PD、HD,或其他因素?能否提供一些背景說明?
- Corporate VP, IR
- Corporate VP, IR
Yes, Matt, it's Mary Kay. We did talk about this when we gave our guidance back in January that we did expect that, given the [yaka] reimbursement that's a biannual every 2-year basically price reduction in Japan, as well as we are seeing some of the EU austerity measures that we discussed, which had for the full year a $30 million to $40 million impact over the total portfolio. But there is a significant portion that's in renal as well. So that will be an ongoing difficult comparison that we'll have going forward.
有的,Matt,我是 Mary Kay。我們在 1 月提供財測時有談到:考量到日本的 [yaka] 給付調整——基本上是每兩年一次的降價——以及我們也看到先前提到的歐盟緊縮措施,這些對全年整體產品組合的影響約為 3,000 萬到 4,000 萬美元。其中也有相當一部分是在腎臟領域。因此,未來我們將持續面臨較艱難的比較基期。
- Analyst
- Analyst
Great. Thanks, Bob; thanks, Mary Kay.
很好。謝謝,Bob;謝謝,Mary Kay。
Operator
Operator
Ladies and gentlemen, this concludes today's conference call with Baxter International. Thank you for participating.
各位女士、先生,今天 Baxter International 的電話會議到此結束。感謝各位參與。